SCHEMBL396466

SCHEMBL396466

O=CN=CCO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12362395 0.67
SCHEMBL2751289 0.67
SCHEMBL9940294 0.67 HIF1A (0.39)
SCHEMBL9751684 0.67
SCHEMBL2283017 0.63
SCHEMBL2752712 0.63
SCHEMBL17668147 0.60
SCHEMBL73703 0.60
SCHEMBL4338859 0.60
SCHEMBL11276924 0.60

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879591-B1 USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS DEVELOGEN AG (DE) 2012-01-25 EP disclosed
US-7968535-B2 Antidiabetic agents; neurodegenerative disorders; mixture with immunosuppresants DEVELOGEN ATKIENGESELLSCHAFT (DE) 2011-06-28 US disclosed
WO-2009010298-A2 PAULLONE DERIVATIVES AND ITS USE TECHNISCHE UNIVERSITÄT CAROLO-WILHELMINA ZU BRAUNSCHWEIG (DE) 2009-01-22 WO disclosed
US-20080287423-A1 Use of Azapaullones For Preventing and Treating Pancreatic Autoimmune Disorders EVOTEC INTERNATIONAL GMBH (DE) 2008-11-20 US disclosed
EP-1879591-A1 USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS DeveloGen Aktiengesellschaft (DE) 2008-01-23 EP disclosed
WO-2006117221-A1 USE OF AZAPAULLONES FOR PREVENTING AND TREATING PANCREATIC AUTOIMMUNE DISORDERS DEVELOGEN AKTIENGESELLSCHAFT (DE) 2006-11-09 WO disclosed